Day One Biopharmaceuticals Newsroom

U.S. Food and Drug Administration Approves FoundationOneCDx as a Companion Diagnostic for OJEMDA (Tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients

BusinesswireJan 17 07:00 ET

J.P. Morgan Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating

Moomoo NewsJan 16 06:31 ET · Ratings

BofA Securities Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsJan 14 07:31 ET · Ratings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Is Breakeven Near?

Simply Wall StJan 14 06:28 ET

Optimistic Outlook for Day One Biopharmaceuticals: Strong Sales Performance and Promising Pipeline Support Buy Rating

TipRanksJan 13 10:35 ET · Ratings

Needham Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $33

Moomoo NewsJan 13 10:33 ET · Ratings

Day One Biopharmaceuticals Announces $57.2M Preliminary 2024 OJEMDA Revenue, Cleared Phase 1a/b DAY301 Dose Cohort, $531.7M In Cash, To Present At J.P. Morgan Healthcare Conference Today At 6:45 P.m. Eastern Time

BenzingaJan 13 08:06 ET

BofA Securities Adjusts Price Target on Day One Biopharmaceuticals to $25 From $28, Maintains Buy Rating

MT NewswiresJan 7 10:52 ET · Ratings

BofA Securities Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $25

Moomoo NewsJan 7 07:31 ET · Ratings

Day One Biopharm Is Maintained at Buy by Jones Trading

Dow JonesDec 17, 2024 12:28 ET · Ratings

Day One Biopharmaceutical Analyst Ratings

BenzingaDec 17, 2024 12:17 ET · Ratings

Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but With Extreme Concentration Risk

TipRanksDec 17, 2024 03:54 ET

JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $34

Moomoo NewsDec 16, 2024 16:31 ET · Ratings

CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors

PR NewswireDec 16, 2024 09:56 ET

Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsDec 5, 2024 11:35 ET · Ratings

Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to Its Board of Directors

BusinesswireDec 3, 2024 08:00 ET

Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?

Yahoo FinanceNov 27, 2024 10:18 ET

JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG

Seeking AlphaNov 25, 2024 13:58 ET

Express News | Day One Announces Retirement of DR. Samuel Blackman, Co-Founder and Head of Research & Development

ReutersNov 20, 2024 16:30 ET

JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas

Seeking AlphaNov 19, 2024 11:06 ET